Evidence map›Paper›PMID 34739906›Full record

ArticleEpidemics2021

Sustaining effective COVID-19 control in Malaysia through large-scale vaccination.

Pavithra Jayasundara, Kalaiarasu M Peariasamy, Kian Boon Law, Ku Nurhasni Ku Abd Rahim, Sit Wai Lee, Izzuna Mudla M Ghazali, Milinda Abayawardana, Linh-Vi Le, Rukun K S Khalaf, Karina Razali and 7 more

Abstract read
In one paragraph

Article in Epidemics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Pavithra JayasundaraSchool of Public Health and Preventive Medicine, Monash University, Australia. Electronic address: pavithra.jayasundara@monash.edu.
Kalaiarasu M PeariasamyInstitute for Clinical Research, National Institutes of Health, Ministry of Health, Malaysia.
Kian Boon LawInstitute for Clinical Research, National Institutes of Health, Ministry of Health, Malaysia.
Ku Nurhasni Ku Abd RahimMalaysian Health Technology Assessment Section, Medical Development Division, Ministry of Health, Malaysia.
Sit Wai LeeMalaysian Health Technology Assessment Section, Medical Development Division, Ministry of Health, Malaysia.
Izzuna Mudla M GhazaliMalaysian Health Technology Assessment Section, Medical Development Division, Ministry of Health, Malaysia.
Milinda AbayawardanaSchool of Public Health and Preventive Medicine, Monash University, Australia.
Linh-Vi LeWorld Health Organization, Regional Office for the Western Pacific, Philippines.
Rukun K S KhalafWorld Health Organization Representative Office to Malaysia, Brunei Darussalam and Singapore, Cyberjaya, Malaysia.
Karina RazaliWorld Health Organization Representative Office to Malaysia, Brunei Darussalam and Singapore, Cyberjaya, Malaysia.
Xuan LeSchool of Public Health and Preventive Medicine, Monash University, Australia.
Zhuo Lin ChongInstitute for Public Health, National Institutes of Health, Ministry of Health, Malaysia.
Emma S McBrydeAustralian Institute of Tropical Health and Medicine, James Cook University, Queensland, Australia.
Michael T MeehanAustralian Institute of Tropical Health and Medicine, James Cook University, Queensland, Australia.
Jamie M CaldwellDepartment of Biology, University of Hawaii at Manoa, HI, USA.
Romain RagonnetSchool of Public Health and Preventive Medicine, Monash University, Australia.
James M TrauerSchool of Public Health and Preventive Medicine, Monash University, Australia.

Funding

World Health Organization 001
6 · The paper itself

Abstract

introductionAs of 3rd June 2021, Malaysia is experiencing a resurgence of COVID-19 cases. In response, the federal government has implemented various non-pharmaceutical interventions (NPIs) under a series of Movement Control Orders and, more recently, a vaccination campaign to regain epidemic control. In this study, we assessed the potential for the vaccination campaign to control the epidemic in Malaysia and four high-burden regions of interest, under various public health response scenarios.

methodsA modified susceptible-exposed-infectious-recovered compartmental model was developed that included two sequential incubation and infectious periods, with stratification by clinical state. The model was further stratified by age and incorporated population mobility to capture NPIs and micro-distancing (behaviour changes not captured through population mobility). Emerging variants of concern (VoC) were included as an additional strain competing with the existing wild-type strain. Several scenarios that included different vaccination strategies (i.e. vaccines that reduce disease severity and/or prevent infection, vaccination coverage) and mobility restrictions were implemented.

resultsThe national model and the regional models all fit well to notification data but underestimated ICU occupancy and deaths in recent weeks, which may be attributable to increased severity of VoC or saturation of case detection. However, the true case detection proportion showed wide credible intervals, highlighting incomplete understanding of the true epidemic size. The scenario projections suggested that under current vaccination rates complete relaxation of all NPIs would trigger a major epidemic. The results emphasise the importance of micro-distancing, maintaining mobility restrictions during vaccination roll-out and accelerating the pace of vaccination for future control. Malaysia is particularly susceptible to a major COVID-19 resurgence resulting from its limited population immunity due to the country's historical success in maintaining control throughout much of 2020.

Indexed as

COVID-19Epidemiological ModelsHumansMalaysiaSARS-CoV-2VaccinationCOVID-19Mathematical modellingVaccinationVariants of concern

Identifiers

PMID34739906
PMCPMC8547797

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.